|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.12.25 - 13:48
|
Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer (Business Wire)
|
|
|
MONTREAL--(BUSINESS WIRE)--#Antibodies--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).
Dr. Maki brings over 20 years of biopharmaceutical industry experience, including leadership roles in business development, licensing, and corporate venture across both emerging biotech ventures and global pharmaceutical companies. Her background includes senior positions at industry-leading organizations such as Medarex (now part of Bristol Myers Squibb), Genentech, Merck & Co., Eli Lilly and Company, and Callio Therapeutics.
In her new role, Dr. Maki will lead Ability's business development strategy, driving global partnering efforts and cultivating new investor relationships to support the company's growth. These strategic collaborations and financing initiatives will help advance autoimmune and oncology programs created with Ability's proprietary Abi...
|
|
|
|
|
|
|
|
|
|
|
|
|
04.12.25 - 14:03
|
Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel (Business Wire)
|
|
|
CARMEL, Ind. & LONDON--(BUSINESS WIRE)--#TYK2--Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Paul S. Bavier, J.D., as Chief Legal Officer.
Mr. Bavier brings more than two decades of legal and executive leadership experience in the biotechnology industry, with deep expertise spanning company formation, financings, mergers and acquisitions, compliance, and public market readiness.
Before joining Sudo, Mr. Bavier served as General Counsel, Secretary and Chief Administrative Officer at HilleVax, Inc., where he was a founding member of the leadership team and helped guide the company through its initial public offering and clinical development milestones. He previously served as General Counsel at VelosBio, Inc. (acquired by Merck & Co.) and Avedro, Inc. (acquired by Glaukos Corporation), where he led corporate governance, compliance, and strategic initiatives. Ear...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
